EUVIMEDEUVIMED entdecken
Open Access

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli

Tingting Xu iD, Weiyuan Wu, Lili Huang, Bin Liu, Qiaodong Zhang, Jingjie Song, Jialong Liu, Bing Li, Zhao Li, Kai Zhou iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00906-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Tingting Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated H…. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Drug Resistance, Multiple, Bacterial, Drug Combinations. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), Shenzhen Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid rise of multidrug resistance (MDR) among Gram-negative bacteria has accelerated the development of novel therapies. Ceftazidime-avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor recently approved for the treatment of limited infectious diseases. Here, we describe a novel CMY variant, CMY-192, that confers high-level resistance to CZA. This gene was detected in a clinical MDR Escherichia coli strain (Ec73552) isolated from an outpatient with a community-acquired urinary tract infection who had not received prior CZA treatment. Ec73552 was typed as O101:H9-ST10, a high-risk clone associated with human and animal diseases. Ec73552 was able to colonize the bladder in a mouse model, suggesting that this strain was uropathogenic. CMY-192 shared the highest amino acid identity (98.95%) with CMY-172 and conferred at least a 32-fold increase in CZA MIC (from ≤0.125/4 to 8/4 mg/L) when cloned into a CZA-susceptible E. coli DH5α strain. Knockout of CMY-192 in Ec73552 resulted in a 256-fold reduction in CZA MIC (from 64/4 to 0.25/4 mg/L). CMY-192 was encoded on an IncB/O/K/Z-type plasmid (pCMY192). Conjugation assays confirmed that pCMY192 was self-transmissible, resulting in a 256-fold increase in the CZA MIC of the recipient. Notably, pCMY192 cured in Ec73552 did not confer a growth advantage, while the conjugant exhibited reduced biomass and growth rate, indicating that fitness costs imposed by pCMY192 may have been compensated in Ec73552. Our findings highlight the importance of continuous monitoring of CZA susceptibility to prevent the spread of resistance in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsDrug Resistance, Multiple, BacterialDrug CombinationsPlasmidsEscherichia coliAnti-Bacterial AgentsMicrobial Sensitivity TestsEscherichia coli InfectionsAnimalsMiceHumansbeta-LactamasesUrinary Tract InfectionsFemale

Stichwörter der Autor:innen

Escherichia coliantibiotic resistanceblaCMY-192ceftazidime-avibactamβ-lactamase

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial Agentsbeta-Lactamases

Autor:innen und Institutionen

  • Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Gua…
  • Department of Pathogen Biology, Shenzhen University Medicine School, Shenzhen, Guangdong, China.
  • Clinical Laboratory, Second Clinical Medical College (Shenzhen People's Hospital), Jinan University; the First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, Gu…
  • Key Laboratory of Molecular Microbiology and Technology, Nankai University, Ministry of Education, Tianjin, China.
  • Nankai International Advanced Research Institute, Nankai University, Shenzhen, Guangdong, China.
  • Shanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, Nation…

ORCID-Profile: Tingting Xu, Kai Zhou

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)
  • Shenzhen Science and Technology Program
  • Guangdong Basic and Applied Basic Research Foundation
  • Guangxi University Young and Middle-aged Teachers' Basic Research Ability Improvement Project

Zitieren

APA

Xu, T., Wu, W., Huang, L., Liu, B., Zhang, Q., Song, J., Liu, J., Li, B., Li, Z., & Zhou, K. (2024). Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00906-24

Vancouver

Xu T, Wu W, Huang L, Liu B, Zhang Q, Song J, et al. Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00906-24

BibTeX
@article{Xu2024,
  author = {Xu, Tingting and Wu, Weiyuan and Huang, Lili and Liu, Bin and Zhang, Qiaodong and Song, Jingjie and Liu, Jialong and Li, Bing and Li, Zhao and Zhou, Kai},
  title = {Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00906-24}
}
Kostenlos starten →